Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of Pittsburgh |
---|---|
Information provided by: | University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT00377286 |
The goal of this study is 1) to develop a biomarker of of cartilage synthesis by determining if there is a relationship between changes in the status of knee cartilage and the amount of a biomarker called CTX-II in urine. 2) We will also characterize people who have experienced cartilage loss and/or reduced functional ability using performance tests and a questionnaire. 3) The administration of glucosamine in a beverage for six months will be used to promote the alteration in cartilage status and improve function in people with mild to moderate joint pain. A secondary goal will be to assess the effect of glucosamine on the skin in a small subset of women.
Condition | Intervention |
---|---|
Osteoarthritis |
Dietary Supplement: Glucosamine (a dietary supplement) Other: 16 oz lite lemonade |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Pharmacodynamics Study |
Official Title: | Development of Biomarker and Functional Assessment Tools to Evaluate the Effect of Glucosamine on Joint Structure and Quality of Life |
Estimated Enrollment: | 200 |
Study Start Date: | September 2006 |
Estimated Study Completion Date: | June 2008 |
Arms | Assigned Interventions |
---|---|
2: Placebo Comparator
1500 mg of lite lemonade
|
Other: 16 oz lite lemonade
16 oz lite lemonade 1 time daily for 6 months
|
1: Active Comparator
1500 mg glucosamine in 16 oz lite lemonade 1 time daily for 6 months
|
Dietary Supplement: Glucosamine (a dietary supplement)
1500 mg in 16 oz lite lemonade, once per day for 6 months
|
Reduced knee function is a significant cause of physical limitations and disability. As cartilage deteriorates due to aging, wear-and-tear, injury, or disease, joint space narrowing and pain can develop. The lost of articular cartilage arises from an imbalance between cartilage synthesis and cartilage degradation. When cartilage needs to be remodeled, enzymes such as matrix metalloproteinases (MMPs) degrade type II collagen. It now may be possible to use new molecular markers of cartilage degradation to assess the progression of joint loss in comparison with radiographic changes of the knee joint. Urinary excretion of C-terminal cross linking telopeptide of type II collagen (CTX-II) is a new molecular marker of cartilage tissue degradation metabolism.
Recent evidence suggests that glucosamine, a dietary supplement, may provide some relief from joint pain and may increase the functional ability to participate in activities of daily living. This may be a result of these dietary supplements stimulating tissue repair such as cartilage in the affected joints, or by inhibiting the degradation of cartilage through an inhibition of enzymes. Moreover, Braham, Dawson, & Goodman (2003) reported increases in function in adults with knee pain following 12 -weeks of glucosamine supplementation. It is unclear, however, if glucosamine delivered via a liquid carrier would improve physical function and impact quality of life measures in people who have experienced loss of knee cartilage.
Glucosamine is a precursor for glycosaminoglycans, which are a major component of both joint cartilage and skin. Potential benefits of glucosamine on skin have been reported previously. It is possible that glucosamine in a beverage might also improve skin parameters over time.
Comparisons: 100 men and women with mild to moderate joint pain taking a liquid with glucosamine, compared to 100 men and women with mild to moderate joint pain taking a liquid with placebo.
Ages Eligible for Study: | 35 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Pennsylvania | |
University of Pittsburgh | |
Pittsburgh, Pennsylvania, United States, 15213 |
Principal Investigator: | John Jakicic, PhD | University of Pittsburgh |
Principal Investigator: | C. Kent Kwoh, M.D. | University of Pittsburgh |
Responsible Party: | University of Pittsburgh ( John Jakicic, PhD ) |
Study ID Numbers: | 0604099 |
Study First Received: | September 14, 2006 |
Last Updated: | December 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00377286 |
Health Authority: | United States: Institutional Review Board |
Osteoarthritis Knee Pain Glucosamine MRI |
CTX-II Biomarkers Skin quality |
Musculoskeletal Diseases Osteoarthritis Joint Diseases Arthritis |
Quality of Life Pain Rheumatic Diseases |